Meet the Speakers: June Raine on Drug Safety and Regulation
Who is June Raine?
June Raine is the Chief Executive Officer of the Medicines and Healthcare products Regulatory Agency (MHRA) and a leading figure in UK pharmacovigilance. Before taking the top role, she spent years as Director of the MHRA's Vigilance and Risk Management of Medicines division, where she shaped how the UK detects, assesses, and responds to drug safety signals.

Her career began in clinical medicine and public health, giving her a patient-centred perspective that still guides her regulatory decisions. Colleagues describe her as methodical, evidence-driven, and unusually skilled at translating complex safety data into practical action.
Building the UK's Pharmacovigilance Framework
Under Raine's leadership, the MHRA strengthened its Yellow Card scheme, expanded real-world data collection, and improved how adverse drug reaction reports are triaged. She has consistently argued that safety monitoring must be continuous, not a one-off hurdle before approval.
She also pushed for greater transparency, including clearer communication of emerging risks to healthcare professionals and the public. That approach helped the agency respond faster during high-profile safety reviews.
Key Milestones and Priorities
Raine's tenure has been defined by several priorities that reshaped UK vigilance practice:
- Modernising signal detection using large-scale clinical databases.
- Strengthening collaboration with international regulators.
- Embedding patient involvement in safety decision-making.
- Improving risk communication during public health emergencies.
These priorities reflect her belief that regulation is a shared responsibility across industry, clinicians, and patients.
How She Works: A Structured Approach
Raine is known for a disciplined, step-by-step method when assessing a potential safety issue. Observers summarise her process as follows:
- Gather and verify the available evidence.
- Assess causality and the strength of the signal.
- Consider the impact on patients and public health.
- Decide on regulatory action and communicate clearly.
- Monitor the outcome and review as new data arrives.
"Safety is not a moment of approval; it is a lifelong commitment to patients," Raine has often said in public remarks.
That philosophy underpins the MHRA's current vigilance strategy and its growing use of digital tools.
What to Expect at the Seminar
At the MHRA advertising seminar, Raine is expected to discuss how pharmacovigilance intersects with advertising compliance. Her session will likely cover common pitfalls in safety claims and the regulatory expectations for promotional material.
Attendees can also expect practical guidance on reporting obligations. The table below outlines the core areas she is likely to address.
| Topic | Focus | Audience Takeaway |
|---|---|---|
| Signal detection | Early identification of risks | Understand reporting triggers |
| Risk communication | Clear, accurate messaging | Avoid misleading claims |
| Compliance | Advertising standards | Align promotions with safety data |
| Patient involvement | Lived experience in decisions | Build trust through transparency |
Her talk promises to connect day-to-day advertising decisions with the wider safety ecosystem that protects patients.
Why Her Perspective Matters
June Raine's career shows how vigilance and regulation are inseparable from public trust. For anyone working in pharmaceutical advertising, understanding her priorities is not optional; it is essential to producing compliant, credible material.
Meet the Speakers: June Raine on Drug Safety and Regulation will offer a rare chance to hear directly from one of the UK's most influential regulators. Her insights will help delegates navigate the fine line between promotion and protection.
